Eagle Bay Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-6,603
Closed -$175K 723
2024
Q4
$175K Sell
6,603
-1,286
-16% -$34.9K 0.11% 124
2024
Q3
$228K Buy
7,889
+49
+0.6% +$1.43K 0.09% 154
2024
Q2
$219K Buy
7,840
+647
+9% +$17.8K 0.13% 112
2024
Q1
$200K Buy
7,193
+1,287
+22% +$35.7K 0.13% 128
2023
Q4
$170K Sell
5,906
-2,070
-26% -$62.6K 0.11% 151
2023
Q3
$265K Buy
7,976
+2,540
+47% +$89.8K 0.12% 113
2023
Q2
$199K Sell
5,436
-3,568
-40% -$139K 0.11% 127
2023
Q1
$367K Sell
9,004
-1,485
-14% -$64.1K 0.2% 77
2022
Q4
$537K Buy
10,489
+12
+0.1% +$575 0.3% 58
2022
Q3
$460K Sell
10,477
-1,789
-15% -$86.9K 0.28% 61
2022
Q2
$643K Buy
12,266
+709
+6% +$36.1K 0.39% 46
2022
Q1
$598K Buy
11,557
+8,929
+340% +$463K 0.49% 34
2021
Q4
$155K Sell
2,628
-8,012
-75% -$397K 0.1% 136
2021
Q3
$459K Buy
10,640
+5,172
+95% +$229K 0.26% 61
2021
Q2
$217K Buy
+5,468
New +$213K 0.17% 80

Other funds holding PFE

Eagle Bay Advisors's PFE Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Pfizer (PFE) in Q1 2025, closing a stake of 6,603 shares — an estimated $175K sold.

Eagle Bay Advisors first reported a position in PFE in Q2 2021 and held it in 15 quarters. The position peaked at $643K in Q2 2022. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 6,603 Pfizer shares in Q1 2025, an estimated $175K.
  • Eagle Bay Advisors first reported a position in Pfizer in Q2 2021 and held it in 15 quarters.
  • Eagle Bay Advisors's Pfizer position peaked at $643K in Q2 2022.
  • 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.